Stock listing

Lang & Schwarz:A3DSHM Lavipharm SA Aktie

German listing (Lang & Schwarz) of Lavipharm SA · home listing ATHEX:LAVI

Follow Lavipharm SA into a list and get an email when it puts out news.

Home listing price · ATHEX:LAVI

€1.45 EUR -0.03 (-1.8%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ATHEX:LAVI

Past year +76.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
€1.41 – €1.48 EURNov 20, 2026
Volume
57,717 sharesNov 20, 2026
Market cap
€246.9M EURAt the close on Nov 20, 2026 · price × 170.8M shares outstanding
52-week range
€0.807 – €1.74 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€127,957 EURMedian day 38,050 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Lavipharm SA logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ATHEX:LAVI · Home€1.446 EUR-0.026 (-1.8%)57,717€1.48€1.48€1.414€1.472Close on Nov 20, 2026
Frankfurt:BXA0€1.368 EUR-0.038 (-2.7%)—€1.378€1.398€1.368€1.406Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ATHEX:LAVI · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€1.446-0.026-1.8%€1.48€1.48€1.41457,717
€1.472-0.01-0.7%€1.478€1.486€1.4610,001
€1.482-0.004-0.3%€1.472€1.496€1.4712,055
€1.486+0.01+0.7%€1.48€1.52€1.4818,246
€1.476-0.002-0.1%€1.464€1.51€1.45224,567
€1.478-0.002-0.1%€1.48€1.49€1.47412,900
€1.48-0.01-0.7%€1.49€1.49€1.4717,801
€1.49+0.002+0.1%€1.49€1.492€1.4727,586
€1.488+0.038+2.6%€1.47€1.50€1.44838,383
€1.45-0.05-3.3%€1.496€1.498€1.44470,019
€1.50-0.026-1.7%€1.53€1.53€1.49855,023
€1.526+0.046+3.1%€1.50€1.534€1.49136,016
€1.48-0.02-1.3%€1.472€1.498€1.47225,253
€1.50-0.036-2.3%€1.534€1.534€1.4965,872
€1.536+0.006+0.4%€1.538€1.538€1.5029,482
€1.53+0.004+0.3%€1.526€1.54€1.51435,375
€1.526+0.008+0.5%€1.536€1.536€1.4941,045
€1.518+0.066+4.5%€1.48€1.55€1.4745,193
€1.452-0.018-1.2%€1.48€1.508€1.43247,951
€1.47-0.028-1.9%€1.48€1.484€1.4740,491
€1.498-0.008-0.5%€1.484€1.518€1.484103,540
€1.506-0.004-0.3%€1.486€1.506€1.4738,050
€1.51+0.002+0.1%€1.51€1.53€1.489,207
€1.508-0.002-0.1%€1.486€1.518€1.4866,052
€1.51+0.002+0.1%€1.48€1.51€1.4831,861
€1.508+0.002+0.1%€1.528€1.53€1.48242,915
€1.506-0.014-0.9%€1.53€1.56€1.49846,701
€1.52+0.01+0.7%€1.56€1.56€1.49239,045
€1.510.000.0%€1.518€1.54€1.49434,442
€1.51-0.02-1.3%€1.53€1.54€1.46287,323
€1.53-0.03-1.9%€1.55€1.55€1.498223,278
€1.560.000.0%€1.56€1.586€1.54419,947
€1.56-0.008-0.5%€1.568€1.586€1.54433,384
€1.568+0.018+1.2%€1.568€1.582€1.53842,029
€1.55-0.024-1.5%€1.574€1.576€1.5514,315
€1.574+0.004+0.3%€1.58€1.58€1.5612,795
€1.57+0.002+0.1%€1.58€1.58€1.55416,420
€1.568-0.002-0.1%€1.586€1.59€1.5434,549
€1.57-0.008-0.5%€1.58€1.58€1.55614,996
€1.5780.000.0%€1.588€1.588€1.55437,839
€1.578+0.014+0.9%€1.59€1.59€1.56225,877
€1.564-0.036-2.3%€1.60€1.60€1.564577,861
€1.60-0.006-0.4%€1.612€1.614€1.58101,215
€1.606-0.004-0.2%€1.60€1.62€1.582291,398
€1.61+0.02+1.3%€1.566€1.61€1.56697,120
€1.59+0.01+0.6%€1.586€1.61€1.56116,996
€1.58+0.032+2.1%€1.534€1.58€1.534181,580
€1.548-0.02-1.3%€1.58€1.58€1.54167,207
€1.568-0.022-1.4%€1.60€1.60€1.55224,032
€1.59-0.008-0.5%€1.598€1.60€1.56429,278
€1.598-0.022-1.4%€1.62€1.62€1.5835,534
€1.62+0.018+1.1%€1.608€1.62€1.58469,340
€1.602-0.008-0.5%€1.608€1.608€1.58228,289
€1.61-0.01-0.6%€1.602€1.618€1.5856,668
€1.62-0.002-0.1%€1.64€1.64€1.59824,809
€1.622-0.018-1.1%€1.65€1.65€1.5985,748
€1.64-0.008-0.5%€1.64€1.666€1.6236,306
€1.648+0.006+0.4%€1.678€1.678€1.63213,277
€1.642+0.002+0.1%€1.64€1.672€1.63232,871
€1.64-0.008-0.5%€1.618€1.69€1.61857,611
€1.648+0.002+0.1%€1.652€1.68€1.644333,147
€1.646+0.086+5.5%€1.568€1.65€1.568452,594
€1.56-0.004-0.3%€1.55€1.584€1.544511,677
€1.564+0.01+0.6%€1.54€1.582€1.5426,845
€1.554-0.012-0.8%€1.57€1.58€1.5523,820

Splits

8 splits since 1997 · ATHEX:LAVI · every price before a split is adjusted for it

DayRatioWhat
1.0743-for-1Split
1-for-3Consolidation
89-for-83Split
73-for-55Split
2-for-1Split
11-for-10Split
95-for-89Split
6-for-5Split
Ticker
Lang & Schwarz:A3DSHM
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
Lang & Schwarz
Currency
EUR

What changed lately

Latest news

All Lavipharm SA news

Lavipharm SA on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
2 in the last 12 months · 13 in all · newest Sep 3, 2026 · oldest 2023
Decks
3 decks · latest Apr 27, 2026

Where Lavipharm SA is listed

ListingExchangeCountryCurrency
ATHEX:LAVI · Home listingATHEXGreeceEUR
Lang & Schwarz:A3DSHM · This pageLang & SchwarzGermanyEUR
LS Exchange:A3DSHMLS ExchangeGermanyEUR
Frankfurt:BXA0FrankfurtGermanyEUR
LSE:0KDJLSEUnited KingdomEUR

Valuation

P/E 41.2× against a median of 52.5×: 2nd lowest of 5 Pharmaceuticals companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
€281.6M EUR
P/E
41.2×
EV/sales
4.5×
EV/EBITDA
22.8×
Price/book
4.4×
Gross margin
46.0%
Operating margin
11.4%
Net margin
9.6%
Debt to equity
0.7×
Beta
No index for this market yet

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lavipharm SA · ATHEX:LAVIUS$271.0MUS$309.1M41.2×4.5×22.8×4.4×9.6%0.7×n/a
Chengdu Huasun Technology Group Inc., Ltd. Class A · SZSE:000790US$285.5MUS$277.5Mn/a4.4×n/a2.7×−57.2%0.1×n/a
Tiansheng Pharmaceutical Group Co. Ltd. Class A · SZSE:002872US$279.7MUS$239.5Mn/a3.1×n/a1.0×−10.6%0.0×n/a
Bukwang Pharmaceutical Co., Ltd. · KRX:003000US$278.6MUS$153.0M42.7×1.0×n/a1.1×4.1%0.0×n/a
Ildong Pharmaceutical Co., Ltd. · KRX:249420US$278.0MUS$233.1M8.6×0.5×6.3×1.4×7.5%0.0×n/a
Deva Holding A.S. · BIST:DEVAUS$276.9MUS$245.0Mn/a0.6×4.4×0.4×−3.9%0.1×n/a
Honz Pharmaceutical Co., Ltd. Class A · SZSE:300086US$276.0MUS$298.2Mn/a5.9×n/a2.2×−62.4%0.2×n/a
Shandong Sito Bio-technology Co., Ltd. Class A · SZSE:300583US$272.2MUS$254.6M62.3×1.5×n/a1.0×2.6%0.1×n/a
Zhejiang East Asia Pharmaceutical Co., Ltd. Class A · SSE:605177US$264.1MUS$340.3Mn/a2.4×n/a1.1×−21.8%0.5×n/a
Jilin Jian Yisheng Pharmaceutical Co., Ltd. Class A · SZSE:002566US$260.3MUS$189.9M66.4×2.1×n/a0.8×4.4%0.1×n/a
Emergent BioSolutions Inc. · NYSE:EBSUS$259.6MUS$598.2Mn/a0.9×n/a0.8×−40.2%1.6×1.17
Median of the othersUS$276.4MUS$249.8M52.5×1.8×5.3×1.1×−7.2%0.1×1.17

Team and board

Officers

OfficerRole
Telemaque Jean LavidasChief Executive Officer
Vassilis BaloumisChief Financial Officer
Vivienne ThomasLead Corporate Communications
Loukia LavidaBoard Vice President
Anastasios SpyropoulosChief Manufacturing & Operations Officer
Artemis PapadakiChief Commercial Officer Hellas
Efi DouniMarketing Director Rx
Eleana NikolopoulouDirector of Legal & Compliance
Emmanouil PetrouHead of Medical Affairs
Ilias KonstantopoulosDirector of Marketing & Sales CHC
Ioannis SarigiannidisChief Commercial Officer International
Katerina KarapaChief Quality Officer
Ligia PanaitescuDirector of Research & Development
Mariza AntonakiChief People & Technology Officer
Nikos LadasChief Scientific Officer
Panagiotis GiannouleasDeputy Chief Executive Officer
Roxani SkartsiouniDirector of Supply Chain & Planning

Board

DirectorRole
Sofia Kounenaki EfraimoglouChairperson of the Board
Christos DiamandopoulosNon-Executive Board Member
James ChristopoulosIndependent, Non-Executive Board Member
Konstantinos RengisNon-Executive Board Member
Loukia LavidaBoard Vice President
Panagiotis GiannouleasDeputy Chief Executive Officer
Telemaque Jean LavidasChief Executive Officer
Vicky D. KefalasIndependent, Non-Executive Board Member

Decks

DeckKindSlidesDate
Investor Presentation (April 2026)Investor deck35 slidesApr 27, 2026
FY2023 Earnings PresentationEarnings36 slidesApr 24, 2024
Investor Presentation (2014)Investor deck25 slides2014

Open Decks

Financials

Annual, in EUR

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue62.6M52.9M50.9M39.1M39.7M37.6M33.6M31.8M31.6M32.0M
Cost of revenue33.8M29.2M27.7M22.7M25.0M22.5M18.6M17.0M17.3M17.5M
Gross profit28.8M23.7M23.2M16.4M14.7M15.1M14.9M14.7M14.2M14.6M
Research and development344.0K285.0K195.0K365.0K812.0K753.0K290.0K410.0K299.0K249.0K
Selling, general and administrative2.85M2.46M2.62M2.33M2.49M2.67M13.8M15.1M15.0M17.5M
Operating income7.16M4.26M4.18M2.69M-398.0K1.96M876.0K-370.0K1.19M-2.63M
Depreciation and amortization5.21M4.58M4.21M1.71M1.65M1.57M1.42M1.18M2.21M3.45M
EBITDA12.4M8.84M8.39M4.39M1.25M3.53M2.30M814.0K3.40M820.0K
Interest expense1.84M2.09M2.27M1.64M1.83M1.92M1.93M1.93M1.99M4.60M
Income before tax7.50M3.60M3.25M2.26M2.75M3.31M2.12M2.86M12.9M11.7M
Income tax2.45M-5.06M1.25M1.31M1.02M1.21M-3.21M1.61M-37.0K2.81M
Net income5.99M8.98M1.87M834.0K1.72M2.09M5.33M1.25M12.9M3.66M
Earnings per share, basic0.040.050.010.040.090.110.290.070.710.20

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents6.11M5.59M8.44M18.2M1.64M1.93M1.73M1.84M2.35M1.68M
Short-term investments3.00K1.00K12.0K44.0K
Receivables22.6M16.1M21.7M15.4M14.5M9.88M12.5M11.6M11.3M13.1M
Inventory23.2M20.8M14.8M10.9M9.59M8.42M6.49M4.90M5.76M6.29M
Current assets53.2M45.0M45.7M45.6M26.0M23.3M20.7M18.6M19.9M21.3M
Property, plant and equipment17.1M17.6M17.0M17.2M15.3M15.3M18.6M
Total assets130.7M125.7M114.8M114.3M53.0M50.6M49.9M41.9M44.9M48.7M
Accounts payable9.75M8.32M9.96M7.77M6.36M2.74M6.03M4.43M3.75M3.94M
Current liabilities44.0M39.1M35.8M45.7M23.2M18.8M17.4M14.7M19.5M41.9M
Long-term debt10.2M12.2M12.7M3.96M4.00M24.0M25.7M26.7M39.8M56.8M
Total debt28.4M33.8M32.4M37.1M37.3M36.3M40.7M40.5M41.5M79.1M
Total liabilities74.3M72.7M72.1M74.0M62.9M62.9M64.3M61.4M64.8M105.6M
Shareholders' equity56.4M53.0M42.7M40.3M-9.98M-12.3M-14.4M-19.5M-19.9M-31.8M
Shares outstanding169.2M168.5M168.2M21.5M18.3M18.3M18.3M18.3M18.3M18.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations6.72M4.80M539.0K3.37M3.84M2.85M2.90M1.43M1.54M622.0K
Capital spending-4.62M-9.64M-4.12M-35.6M-1.92M-1.48M-2.42M-1.03M-350.0K-97.0K
Free cash flow2.10M-4.85M-3.58M-32.2M1.92M1.38M483.0K398.0K1.19M525.0K
Cash from investing-993.0K-9.66M-3.71M-35.6M-1.91M-1.48M-2.41M-1.03M250.0K418.0K
Cash from financing-5.35M2.16M-6.63M48.8M-2.23M-1.18M-595.0K-904.0K-1.11M97.0K
Dividends paid-3.38M
Share buybacks-200.0K0-2.50M49.3M
Change in cash517.0K-2.85M-9.81M16.6M-294.0K200.0K-110.0K-506.0K673.0K1.14M

Open Financials

Cap table

Built by 6ix from Lavipharm SA’s releases

Common shares
170,778,483
Fully diluted
170,778,483

Fully diluted

LineShares
Common shares170,778,483

Share count over time

CountShares
Nov 22, 2026170,778,483

Open Cap table

Shareholders

HolderSharesValueChangeAs of
Emerging Markets Core Equity 2 Portfolio167KUS$308K+6,439Jul 31, 2026
Dimensional Emerging Markets Core Equity 2 ETF59,961US$110K+49,131Jul 31, 2026
Emerging Markets Social Core Equity Portfolio16,249US$29,864+9,837Jul 31, 2026
Emerging Markets Sustainability Core 1 Portfolio13,888US$25,524No changeJul 31, 2026
Emerging Markets ex China Core Equity Portfolio11,544US$21,216NewJul 31, 2026
Dimensional Emerging Markets ex China Core Equity ETF212US$388No changeJul 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anastasios SpyropoulosChief Manufacturing & Operations Officer · Since at least Sep 3, 2026
Artemis PapadakiChief Commercial Officer Hellas · Since at least Nov 5, 2026
Christos DiamandopoulosNon-Executive Board Member · Since at least Nov 5, 2026
Efi DouniMarketing Director Rx · Since at least Nov 5, 2026
Eleana NikolopoulouDirector of Legal & Compliance · Since at least Nov 4, 2026
Emmanouil PetrouHead of Medical Affairs · Since at least Nov 5, 2026
Ilias KonstantopoulosDirector of Marketing & Sales CHC · Since at least Nov 5, 2026
Ioannis SarigiannidisChief Commercial Officer International · Since at least Nov 5, 2026
James ChristopoulosIndependent, Non-Executive Board Member · Since at least Nov 5, 2026
Katerina KarapaChief Quality Officer · Since at least Jun 11, 2026
All 22 people
PersonSeat
Konstantinos RengisNon-Executive Board Member · Since at least Nov 5, 2026
Ligia PanaitescuDirector of Research & Development · Since at least Nov 5, 2026
Loukia LavidaBoard Vice President · Since at least Nov 5, 2026
Mariza AntonakiChief People & Technology Officer · Since at least Nov 5, 2026
Nikos LadasChief Scientific Officer · Since at least Nov 5, 2026
Panagiotis GiannouleasDeputy Chief Executive Officer · Since at least Nov 5, 2026
Roxani SkartsiouniDirector of Supply Chain & Planning · Since at least Nov 5, 2026
Sofia Kounenaki EfraimoglouChairperson of the Board · Since at least Nov 5, 2026
Telemaque Jean LavidasChief Executive Officer · Since at least Jan 23, 2025
Vassilis BaloumisChief Financial Officer · Since at least Sep 18, 2025
Vicky D. KefalasIndependent, Non-Executive Board Member · Since at least Nov 4, 2026
Vivienne ThomasLead Corporate Communications · Since at least Sep 3, 2026

Open People

Log in to ask 6ix AI your own questions about Lavipharm SA.